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Lymphomas with testicular localisation show a consistent BCL-2
expression without a translocation (14;18): a molecular and
immunohistochemical study
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Summaiy The presence of the BCL-2 protein was studied in nine non-Hodgkin's lymphomas with testicular
localisation. A consistent presence of the BCL-2 protein was found. The chromosomal translocation (14;18)
was seen neither by cytogenetic analysis (n = 4) nor by polymerase chain reaction amplification and Southern
blotting (n = 9). Therefore, this translocation is not responsible for the presence of the BCL-2 protein in
non-Hodgkin's lymphomas with testicular localisation. We suggest that the presence of the BCL-2 protein in
these lymphomas is related to the differentiation stage of the B-lymphocytes or may play a role in the
pathogenesis of these lymphomas. The consistent finding of the BCL-2 protein in lymphomas with testicular
localisation may support the clinical observation that these lymphomas are a separate entity.
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Non-Hodgkins lymphomas (NHLs) localised to the testis are
extremely rare. They may occur as a primary manifestation
or in the context of dissemination of nodal NHL (secondary
testicular NHL) (Doll and Weis, 1986; Hamilton and Hor-
wich, 1988; Martenson et al., 1988; Lukes and Collins, 1992).
Thus far, there are no criteria to discriminate between these
two. These NHLs of the testis are usually diffuse large-cell
NHLs according to the Working Formulation for lym-
phomas (Doll and Weis, 1986; Hamilton and Horwich. 1988;
Martenson et al., 1988; Lukes and Collins, 1992). The prog-
nosis of NHL with testicular localisation is poor; most
patients die of disseminated NHL within 2 years. In addition,
they show a specific pattern of metastases, e.g. extranodal
sites such as the upper airways, central nervous system and
bones are especially involved (Doll and Weis, 1986; Hamilton
and Horwich. 1988).
Translocation between chromosomes 14 and 18
[t(14q32;18q21)] is found in 60-85% of follicular NHLs and
20-30% of diffuse large-cell NHLs (Aisenberg et al., 1988;
Rowley, 1988; Griesser and Lennert, 1990; Pezzella et al.,
1990a; Lambrechts et al.. 1992; Limpens et al., 1992).
Because of the t(14;18) the B-cell lymphoma 2 (BCL-2) gene
located on the long arm of chromosome 18 is juuxtaposed to
the joining (JH) region of the immunoglobulin heavy-chain
(IgH) gene located on the long arm of chromosome 14
(Tsujimoto et al., 1984; Bakhshi et al., 1985; Cleary & Sklar,
1985; Korsmeyer, 1992). This results in an enhanced expres-
sion of the BCL-2 gene, which subsequently results in a
disturbed programmed cell death (PCD). i.e. a prolonged cell
survival (Vaux et al., 1988; Hockenbery et al., 1990; Nunez et
al., 1990; Henderson et al., 1991; Garcia et al., 1992).
In follicular NHL, diffuse large-cell NHL and NHL of the
gastrointestinal tract, the BCL-2 protein is found using
immunohistochemistry (Ngan et al., 1988; Pezzella et al.,
1990b; Zutter et al., 1991; Gaulard et al., 1992; Kondo et al.,
1992; LeBurn et al., 1992). Presence of the BCL-2 protein is
also reported in normal lymphoid cells and is demonstrated
in precursor cells of all haematopoietic lineages, memory B
cells and plasma and mantle zone B cells (Hockenbery et al.,
1991; Nunez et al. 1991; Pettersson et al. 1992). In nearly all
follicular NHLs, independent of the presence of the t(14;18),
the BCL-2 protein is present (Ngan et al., 1988; Pezzella et
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al., 1990b; Gaulard et al., 1992). In 22-80% of diffuse
large-cell NHLs the BCL-2 protein is found and is not
restricted to those with the t(14;18) (Ngan et al., 1988;
Pezzella et al., 1990b; Zutter et al., 1991; Kondo et al., 1992).
NHLs of the gastrointestinal tract, neoplasms in which
t(14;18) occurs infrequently, exhibit the BCL-2 protein in
about 50% of cases (Kondo et al., 1992; LeBurn et al., 1992).
Thus, the BCL-2 protein is found in normal lymphoid cells
and in many different histological subtypes of NHL indepen-
dent of the presence of the t(14;18).
In the context that NHLs with testicular localisation show
a separate clinical identity among NHL, we investigated the
presence of the t(14;18) by combining cytogenetic analysis
(n = 4), polymerase chain reaction (PCR) and Southern blot-
ting (n = 9). The presence of the BCL-2 protein was studied
using immunohistochemistry on frozen tissue sections (n = 9).
Material and methods
Samples
Tumour samples were collected in The Netherlands from
nine patients with NHL localised in the testis. The tumours
were classified according to the Working Formulation for
lymphomas by a panel of pathologists (National Cancer
Institute sponsored study of classification of non-Hodgcin's
lymphomas, 1982). Staging was according to the Ann Arbor
classification (Carbone et al., 1971). Representative frozen
tissue sections were used for immunohistochemical and
immunofluorescence analysis (Lambrechts et al., 1992).
Immunohistochemistrv
Frozen tissue sections were fixed in acetone (100%) for
10 min. Endogenous peroxidase activity was blocked using
0.3% hydrogen peroxide in phosphate-buffered saline (PBS),
containing 0.2% bovine serum albumin (BSA). Expression of
the BCL-2 protein was studied using a mouse monoclonal
antibody, BCL-2 lOOa (kindly provided by Drs F Pezzella
and DY Mason; Pezzella et al., 1990b). Visualisation was
performed using an indirect peroxidase assay with a
streptavdin-biotin-conjugated goat anti-mouse immuno-
globulin antibody as a second step. Hyperplastic lymph
nodes were used as positive controls.DB-2 and I ada r_nooddn's lymphoma
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Immunofluorescence
Surface marker analysis was performed by direct
immunofluorescence with fluorescein isothiocyanate (FITC)-
conjugated goat anti-human IgM, IgD, IgG, IgA and lambda
serum and tetramethylrhodamineisothiocyanate (TRITC)-
conjugated goat anti-human kappa and lambda serum (Nor-
dic Immunological Laboratories Tilburg, The Netherlands).
Double staining was performed with TRITC-conjugated goat
anti-human kappa plus FITC-conjugated goat anti-human
lambda or with the FITC-conjugated antibody against the
heavy chain expressed by the malignant B-cell plus TRITC-
conjugated anti-kappa or anti-lambda.
Cytogenetic analysis
Cytogenetic analysis was performed on metaphase spread
chromosome of four cases according to standard procedures
(Gibas et al., 1984). The chromosomes were identified with G
banding (GTG banding) and described according to ISCN
1991 (Mittelman, 1991).
DNA extraction andpolymerase chain reaction (PCR)
analjysis
High molecular weight DNA was isolated from frozen tissue
sections of all NHLs with testicular localisation. DNA was
digested with HindIII and analysed for t(14;18) and
immunoglobulin heavy-chain rearrangement (IgH) using
Southern blotting and probing with BCL-2 (Bakhshi et al.,
1985) and the joining region of IgH allele (JH) (Takahasi et
al., 1980). In addition, PCR was used to detect small
amounts of t(14;18)-positive cells. PCR primers were
designed for the major breakpoint region (mbr: 5'-
GGTGGTTTGACCTTTAGA-3') of the BCL-2 gene and the
consensus region of the JH genes (5'-TGAGGAGACG-
GTGACC-3') (Lambrechts et al., 1992). As a control to
DNA quality the interleukin-3 gene of the DNA was ampli-
fied in 25 cycles, as described previously (Lambrechts et al.,
1992). For the detection of t(14;18) a total of 0.5-1.Oig of
DNA in a reaction volume of 25-501lI was subjected to 30
cycles of PCR amplification using an automated Perkin-
Elmer/Cetus DNA thermal cycler (Gouda, The Netherlands).
In each experiment positive and negative controls were
included. As positive controls different dilutions of DNA
from a mbr t(14;18)-positive cell line (SU-DHL-6) or DNA
from a mcr t(14;18)-positive lymph node biopsy was used.
Amplified samples were analysed as described using the BCL-
2 and JH probes (Lambrechts et al., 1992).
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Results
The age of the patient. the localisation and the stage of
disease at diagnosis, response to treatment, the localisation of
metastasis at relapse and the histological subtype of the
non-Hodgkin's lymphoma localised in the testis are sum-
marised in Table I. Additional data concerning the results of
Southern blotting analysis for IgH rearrangements and PCR
for t(14;18) and the screening for BCL-2, immunoglobulin
heavy-(IgH) and light-chain (IgL) proteins are also presented
in Table I.
Of the four NHLs in which cytogenetic analysis was per-
formed, the representative karyotypes are summarised in
Table II. Besides multiple chromosomal abnormalities, no
translocation t(14;18)(q32;q21) was detected. The karyotype
of case 3 is presented in Figure 1. In addition, none of the
NHLs with testicular localisation showed evidence of the
presence of t(14;18) by PCR and Southern analysis.
Immunological phenotyping of the NHL with testicular
localisation showed that all are B-cell NHLs. Monoclonality
of the B-cell population was demonstrated by the expression
of either kappa or lambda in all biopsies. Monoclonality was
confirmed by Southern blot analysis in eight of the nine
NHLs by the detection of a rearranged IgH gene using a
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Table I1 Representative karyotypes of four non-Hodgkin's lymphomas localised in the testis (cases 3.
4, 5, 9, Table I)
Case Description
3 45. X. -Y. del(2Xp12pp3), add(3Xq26.1). del(4Xq22), del(5XqI5q3I), del(6)(p24).
del(6Xq21q23), add(7Xq22). del(9)(p23). add(10)(p12),
der(llXl)lpter-> 1lq25::1lq25-> 1lq22::?), r(12), i(l7XplO), i(l7XqlO), add(l9Xpl3)
4 49. dup(XXp2Ip22.2). -Y. del(6)(q23), del(6Xql5), +8, t(ll;l4Xpll;qll), +12, +13,
del(14q31), + 18
5 88, XXYY, +Y. +Y, add(lXq31) x 2, -2, -5, add(7)(q21) x 2, i(7XqlO), -8,
add(8)q24) x 2. -9, -99, -9, -9, -10, -11 -11, del(I1Xq22q23), -12, -14, -15.
- 16, -16, - 17, -17, - 17, -17, add(18Xq21) x 2, - 19, - 19, +der(?)t(?;5)(?;q13),
+der(?)t(?;17X?;q21) x 2, +marl, + 12mar
9 88, XXYY, add(l)(pll), del(2)(plI.I). -3, -4, add(6Xql5), add(6Xql6) x 2, +7.
t(7;I9XqlI.2;qI3). -11, -12, -13, -13. -15, -15, -17, add(19)(p13.1), -20, -22.
+marlx2, +4mar
Figure I A representative karyotype ofone non-Hodgkin's lymphoma with testicular localisation stage II (case 3, Tables I and II).
probe specific for the JH region. In case 2 monoclonality was
not confirmed by the detection of a rearranged JH fragment.
This might be caused by the fact that the germ line and
rearranged fragments were identical in size. The BCL-2 pro-
tein was consistently present in the cytoplasm of all lym-
phoma cells of the NHL with testicular localisation. A
representative example is given in Figure 2.
Diession
NHLs localised in the testis are high-grade malignant NHLs
and usually of B-lymphocyte origin. They constitute approx-
imately 1% of all lymphomas and have a specific clinical
course of disease. They metastasise to uncommon sites for
other lymphomas, for instance the central nervous system
(Doll and Weis, 1986; Hamilton and Horwich, 1988).
Cytogenetic analysis of four of the NHLs with testicular
localisation revealed many different and complex
chromosomal abnormalities but no chromosomal transloca-
tion (14;18) as found in other histological subtypes of NHL
Figue 2 A representative example of the imnunohistochemical
detection of the BCL-2 protein on frozen tissue sections of a
non-Hodgkin's lymphoma with testicular localisation (case 3, Table
I).BCL-2 and besdw non4iod9bn's yphomas
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(Aisenberg et al., 1988: Rowley, 1988; Gnresser and Lennert,
1990; Pezzella el al.. 1990a; Lambrechts et al.. 1992; Limpens
et al., 1992). In addition, we used PCR analysis, a technique
able to detect one t(14;18)-positive cell out of 100 000 normal
cells, to evaluate nine cases of NHL with testicular localisa-
tion for the presence of t(14;18)-positive cells. No t(14;18)-
positive cells were detected in these NHLs. The presence of
the BCL-2 protein in different histological subtypes of NHL
without t(14;18) was the reason for evaluating the involve-
ment of the presence of the BCL-2 protein in NHL with
testicular localisation as well (Kondo et al., 1992; LeBurn et
al., 1992). While the BCL-2 protein was present in normal
lymphoid cells. no BCL-2 protein was reported in normal
testis (Hockenbery et al., 1991: Nunez et al., 1991; Pettersson
et al.. 1992). Our data show the presence of the BCL-2
protein in all of the NHLs with testicular localisation
studied. Thus. in all cases of NHL with testicular localisation
we studied, the BCL-2 protein is consistently present without
a t(14;18). In spite of the relatively small number of cases,
this finding supports the clinical observation that NHL with
testicular localisation may represent a separate subgroup of
large-cell lymphomas which is distinct from progressed fol-
licular lymphoma. The presence of the BCL-2 protein may
represent a differentiation stage of the B lymphocyte or a
functional subpopulation of B lymphocytes.
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